A Review of Recent Advance Therapy of The MDR TB and DR TB

Abstract

TB still causes a significant amount of illness and mortality across the world, even after the low-cost and successful four-drug treatment regimen (isoniazid, rifampicin, pyrazinamide, and ethambutol) was introduced 40 years ago. For all types of tuberculosis, new and innovative medications and treatment plans are being developed for the first time since the 1960s. Both novel chemical entities and repurposed medications are anticipated to be used in such regimens, some of which are now advancing through clinical studies. Current ideas and recent developments in TB drug discovery and development are discussed in this article. These include an update on ongoing TB treatment studies, updated clinical trial designs, TB biomarkers, and adjunct host-directed medicines.

Keywords

Introduction

        <a href="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250422132514-1.png" target="_blank">
            <img alt="1.png" height="150" src="https://www.ijpsjournal.com/uploads/createUrl/createUrl-20250422132514-1.png" width="150">
        </a>
1.3. Physiology Of Lungs:

Table 2: Classification Of Anti-Tuberculosis Drugs

5.0. Treatment OF MDR-TB

There should be at least four medications with a specific level of efficacy in treatment plans [1]. Patients can receive treatment using either the conventional MDR regimen or a customized regimen based on the drug sensitivity test (DST) following a confirmation diagnosis of MDRTB. MDR-TB suspects will be identified as contacts of MDR-TB cases, any patient who does not react to treatment of Category 1 or Category 3, and any category 2 patient who is still smear positive at the conclusion of the fourth month of therapy. Culture sensitivity and medication resistance tests will be used to evaluate these. Proceed with the Category 2 or Category 1 regimen if the patient is verified to be a non-MDR-TB case; however, if MDR-TB is verified, then Cat. It is time to begin the fourth regimen. The standard therapy for MDR-TB under the Revised National Tuberculosis Control Programme (RNTCP) is the Category 4 regimen. Six medications are included in the category fourth regimen: four bactericidal medications (Ofx or Levofloxacin), Kanamycin, ethionamide, pyrazinamide, and two bacteriostatic medications (Ethambutol and Cycloserine, Cs) were administered during the 6–9 months of the intensive phase (IP), and four medications (Ofloxacin, Levofloxacin, Ethionamide, and Cycloserine) were administered during the 18-month continuation phase (CP). If any of the two bacteriostatic medications—ofloxacin (Ofx) or levofloxacin (Lfx); kanamycin; ethionamide; or pyrazinamide—are not tolerated, PAS is added to the regimen as a backup.

5.1. Duration of treatment

The course of therapy is broken down into two stages: the six-month initial intensive phase (IP) and the 18-month continuation phase (CP). When the fourth month culture results are obtained at the end of the sixth month, the patient is reassessed after six months of therapy, and if the findings are negative, the treatment is switched to CP. Treatment is prolonged for an additional month if the 4-month culture result is still positive. Based on the findings of the fifth- and sixth-months’ sputum cultures (which will be available at the end of the seventh month), the decision to extend IP beyond one month will be made. Regardless of the culture result (either positive or negative), the patient will be started on the CP after the IP has been prolonged for a maximum of three months, or nine months, depending on the results. For CP, the length is 18 months

5.2. General guidelines to treat MDR-TB

Use a minimum of four medications that have a particular level of efficacy.

(a) Avoid using medications that may cause cross-resistance.

b) Get rid of medications that are unsafe, such as those with a known severe allergy or a high risk of serious adverse drug reactions (using two amino-glycosides pharmaceuticals at once),

(c) use medications from groups 1 through 4 in a hierarchical manner based on their potency. [6 or 9 kanamycin, ofloxacin, ethionamide, cycloserine, pyrazinamide, ethambutol/18 ofloxacin, ethionamide, cycloserine, ethambutol] is the preferred standardized regimen as suggested in the national DOTS-Plus recommendations. A thorough history of prior anti-TB medication may be obtained before implementing a tailored regimen in such individuals, provided the findings of second line DST are available.

5.3. New alternative therapies for MDR TB

β-lactamase inhibitors and β-lactam antibiotics. ^{[17] [18]} Linezolid (Lzd)
^[19,20] Phenothiazines 3,5-disubsituted thiadiazinethione, thioridazine, and chlorpromazine.

• Ethyl-5-phenyl-6-oxa-1-azabicyclohexane-2-carbopxylate derivative is an antimalarial drug. ^[21]
• DETA-NO is a nitric oxide donor. ^[22]
• Plant extracts: Lantana hispida's hexane extract. ^[23]
• Snake venom: Naja-atra, a snake isolated from China's Yunnan province, has the small peptide vgf-1. ^[24]
• Azoles: They impede the action of Cyp-450. ^[25]
• Tuberactinomycin: In both structure and method of action, tuberactinomycin is similar to viomycin. It works by preventing the creation of proteins. ^[26]
• Clofazimine (Cfz), a bright-red dye that is a substituted amino-phenazine, suppresses transcription by binding preferentially to mycobacterial DNA and inhibiting mycobacterial growth. Other riminophenazines include B 746, B 4157, and Cfz. ^[27]

5.4. Combination Therapy As The Advance MDR TB

We can better understand why MTB infections can be difficult to cure and need multiple medications for prolonged periods of time by understanding the disease pathophysiology of TB. Pulmonary tuberculosis pathology entails a coordinated immune response comprising many cell types that change as the illness progresses and is treated. Because the infectious environment is dynamic and complicated, Mtb has to be able to withstand a range of stimuli and have the physiological adaptability to change with its surroundings.  Organized, inflammatory, and immunological in nature, the pulmonary lesions of tuberculosis illness are composed of many cell types encircling an intracellular or extracellular Mtb core. Numerous forms of lesions, or granulomas, have been identified; each has its own unique immune cell composition, organization, host cell necrosis levels, and eventual cavitation. In both people and animals, necrotic and cavitating lesions are more challenging to cure and are linked to elevated levels of extracellular Mtb. ^[28]

5.5 Multidrug Therapies Reduce Treatment Time and Drug Resistance Development

One of the biggest problems in treating illnesses like cancer and bacterial infections is drug resistance. The longer a medicine is exposed, the more likely it is that resistance will develop. Thus, the months-long duration of TB therapy is adequate for the development of resistance. Drug resistance can happen when cells develop a factor that enables them to survive in the presence of drug concentrations that would inhibit or kill cells without the factor (for instance, a mutation in the drug target or a mutation that boosts the production of an efflux pump). A medication loses its effectiveness at therapeutically meaningful doses once resistance develops due to these heritable variables; the resistant population can persist and grow into the area that the now-killed susceptible bacteria originally inhabited.^[29] One tactic that can stop resistance from developing in both clinical and experimental settings is the combination of many medications that target distinct biological functions. Targeting different vital cell functions reduces the possibility that a single cell will be resistant to many medications at once. Multidrug treatments for tuberculosis have historically demonstrated better cure than single-drug treatments, with fewer patients relapsing with drug-resistant Mtb. Mtb bacilli would be triple drug-resistant if the clinically established spontaneous streptomycin resistance rate of one in 105 were used as a benchmark. Because there should be fewer than one spontaneously triple drug-resistant Mtb cell in a seriously infected patient, multidrug treatments including more than three medications should be beneficial. This is based on the severe case of cavitary illness bacillary load. According to these computations, the effectiveness of three and four-drug regimens for the treatment of tuberculosis supports the possibility of multidrug therapy success. ^[30] During the early studies with S and PAS, there was a clinical demonstration of reduced resistance development. S monotherapy caused 20% of patients to acquire resistance in one early research, while 70% of patients in the Medical Research Council's (MRC) randomized control trials in the UK developed streptomycin resistance. However, the MRC research revealed that streptomycin resistance was identified in as little as 9% of patients when PAS was given every three days, and in 41% of individuals receiving both S and PAS. The need for combined treatment to stop the development of resistance was shown by these early investigations. Thus, it is not unexpected that at least three medications are used in the creation of short-course therapy for the treatment of tuberculosis. Combination therapy is necessary to protect against variations in access and susceptibility to Mtb that reside in various lesions, as clinical trials have shown. Therefore, medications used in combination therapy should work together to quickly lower the bacterial load before sterilizing persister cells. ^[31]

5.6. New Era of Combination Therapy Design

The discovery and design of medication combinations, as well as the optimization of combination therapy, have relied heavily on the use of animal and in vitro models of tuberculosis. The models, their applications, and computational techniques that will help in discovering novel combinations and creating TB treatment plans in the future will be covered in the parts that follow. ^{[32, 33]}

5.7. Preclinical Animal Models of TB Disease

It is impossible to examine the vast drug combination space that has to be investigated with new medications in a clinic. Animal models have been thoroughly examined and are crucial for assessing medications and treatment combinations in contemporary TB regimen formulation. Testing in preclinical mouse models of tuberculosis illness provided significant support for the inclusion of the medications mentioned in the aforementioned clinical trials (e.g., moxifloxacin, Bedaquiline, and Pretomanid) as possibly treatment-shortening medications in regimens. Although it is not possible to systematically assess the effectiveness of medication combinations in animal models, examination in animal models is necessary prior to moving on to clinical trials. Animal models and their applications in medication combination design will be briefly discussed. ^[48,49,50] Since streptomycin was first introduced, animals have been used to assess the effectiveness of novel TB medications and treatment plans. Furthermore, animal research has been essential to our comprehension of disease pathophysiology, Mtb biology, and host response to infection. Although mice are the most commonly utilized animal models, the majority of their strains do not exhibit many of the clinical characteristics of tuberculosis in humans. Although the granulomas in other animal models—such as guinea pigs, rabbits, and non-human primates—are more similar to those in human illness, they are not suitable for large-scale medication treatment effectiveness investigations. ^[51,52] Due to their widespread usage in basic research, low cost, simplicity of genetic alteration, ease of handling, and comparatively low medication requirements, mouse models of tuberculosis are the most feasible and cost-effective for drug effectiveness testing. The most widely utilized mouse strains, such as BALB/c, C57BL/6, and Swiss, do not develop caseous, necrotic lesions or cavitations that are indicative of human illness; instead, they develop lesions where Mtb is intracellular. These strains have been useful in assessing novel medications and therapeutic combinations, and drug effectiveness trials employing them have yielded a substantial quantity of data despite these and other limitations. ^{[53, 54]}  In mice, pyrazinamide and rifampicin were demonstrated to have treatment-shortening effects. In animal trials, the recently authorized combination of linezolid, pretomanid, and bedaquiline demonstrated to be an effective therapy for drug resistance. These mouse strains will remain important in preclinical drug effectiveness testing due to these successful instances and the above-mentioned practical considerations. ^[55] Drug effectiveness investigations have more recently employed the C3HeB/FeJ mouse strain. These animals develop a variety of lesion forms, including intracellular lesions (like those seen in BALB/c mice), intracellular lesions enriched with neutrophils, and ones with caseous, necrotic centers that resemble human lesions in pathology. Additionally, C3Heb/FeJ mice exhibit varied pharmacological reactions. Pyrazinamide is used to treat both treatment-responsive and non-responsive mice, which is believed to be impacted by different types of lesions. The C3HeB/FeJ strain is useful for assessing medication combinations that exhibit clinical efficacy, according to research on drug combination efficacy. ^[56,57,58] Although rats were thought to be too resistant to Mtb infection to be of much value, they are frequently employed in toxicology and pharmacology research to assess the pharmacokinetics of medications. Recent research has revealed that Wistar rats can contract the disease and have symptoms that are comparable to those of mice. Moreover, as mice could not get the best possible medication exposure, a DprE inhibitor was examined in a rat infection model. Future development of this animal model for examining the pharmacokinetics and effectiveness of medication combinations seems promising due to the widespread usage of rats in toxicology. ^[59,60,61] Non-human primates (NHP), rabbits, and guinea pigs develop lesions with caseation necrosis; rabbits and NHP may also exhibit cavitation. These animal models are crucial for assessing the effectiveness of drugs since they mimic human diseases. In the middle of the 20th century, guinea pigs were the recommended animal model and had a significant impact on the creation of the first TB medication regimens. The caseous necrotic lesion includes a lot of extracellular Mtb throughout medication treatments, and recent investigations of combination therapy effectiveness in mice demonstrated comparable results. Because they are larger, more costly, and need more medications throughout treatment because they clear pharmaceuticals more quickly than mice, guinea pigs are likely to continue to be used as models for follow-up research despite these benefits. ^[62]  After contracting Mtb, rabbits develop lung cavities and caseating necrotic lesions. Lung cavity formation in humans is linked to lengthier TB therapy, illness recurrence, and resistance development. Furthermore, pharmacokinetic and medication distribution investigations in caseous lesions have revealed parallels to human behaviour. Although rabbit models of tuberculosis illness will continue to offer valuable information on the pharmacological treatment of refractory lesions, mice will still be used to assess the efficiency of drug combinations at an early stage of research because of their size, cost, and other drawbacks. ^[62,63] The symptoms and variety of medication treatment results that occur in human TB illness are also present in non-human primates infected with Mtb, along with the pathological markers, such as cavitation. Drug TB illness and the effectiveness of therapy have been studied in cynomolgus macaques and, more recently, marmosets. When compared to an earlier medication combination that contained streptomycin, a research conducted on marmosets revealed that the present four-drug standard of care was more effective in treating cavitary lesions. Experiments conducted in NHPs yield extensive information that helps us comprehend medication combination efficacies in the setting of immunological reactions that are similar to those in human illness, despite the essential paucity of drug combinations that can be evaluated in NHPs. ^{[64, 65]}

6.0. CONCLUSION:

The current MDR-TB epidemic is the result of ignorance for an important infectious disease, lack of resources for TB control programs, poor case detection, and inadequate/inappropriate therapy. Optimization of treatment regimens along with rapid diagnosis and DST for first- and second-line drugs, greatly improved the clinical outcome. Recent advances in diagnosis of MDR-TB and empirical treatment of patients with several drugs in the initial phase of treatment have further improved the prognosis of MDR-TB. The new anti-TB drugs that are in various stages of development also offer hope that we will not soon run out of treatment options against TB and MDR-TB. This review has summarized the drugs used to treat MDR-TB, common adverse drug reactions occurring during MDR-TB treatment and their management and has highlighted the importance of preventing the development and dissemination of this man-made disease.

REFERENCES

1. Indian journal of tuberculosis a review of recent advances in anti-tubercular drug development Volume 67, Issue 4, October 2020, Pages 539-559
2. Anil Kour, Eric Arnoult, Nacer Lounis, Jerome Guillemont & Koen Andries, “The challenge of new drug dixcovery for tuberculosis”, Nature, 469, 2011, 483-490
3. Ying Zhang, Katrin Post-Martens and Steven Denkin, “New drug candidates and therapeutic targets for tuberculosis therapy”, Drug Discovery Today, 11, 2006, 21-27
4. World health organization, multidrug and extensively drug-resistance TB (M/XDR-TB)
5. Standring, S. (2016). Gray’s Anatomy: The Anatomical Basis of Clinical Practice. 41st Ed.
6. Moore, K. L., & Dalley, A. F. (2013). Clinically Oriented Anatomy. 7th Ed.
7. Netter, F. H. (2018). Atlas of Human Anatomy. 7th Ed.
8. Guyton, A. C., & Hall, J. E. (2020). Textbook of Medical Physiology (14th ed.).
9. West, J. B. (2021). Respiratory Physiology: The Essentials (11th ed.).
10. Boron, W. F., & Boulpaep, E. L. (2017). Medical Physiology (3rd ed.).
11. Tortora, G. J., & Derrickson, B. H. (2017). Principles of Anatomy and Physiology Wiley.
12. Silverthorn, D. U. (2018). Human Physiology: An Integrated Approach. Pearson.
13. National Heart, Lung, and Blood Institute (NHLBI): https://www.nhlbi.nih.gov/
14. World Health Organization (WHO). (2023). Guidelines for the Treatment of Drug-Resistant Tuberculosis. Available at: https://www.who.int/tb/publications
15. Conradie, F., et al. (2020). High treatment success rate for XDR-TB with BPaL regimen. New England Journal of Medicine. DOI: 10.1056/NEJMoa1901814
16. Global Tuberculosis Report (2023). World Health Organization.
17. RNTCP DOT Plus Guidelines, Jan. 2010. Available from: http://www.tbcindia.org/pdfs/DOTS_Plus_Guidelines_Jan2010.pdf. [Last accessed on 2011 May 30].
18. Dincer I, Ergin A, Kockagoz T. The vitro efficacy of b-Lactam and b-Lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium Tuberculosis. Am J Resp Crit Care Med 2004; 169:1103-9.
19. Rodriguez Diaz JC, Ruiz M, Lopez M, Royo G. Synergic activity of fluoroquinolones and Linezolid against mycobacterium Tuberculosis. Int J Anti-microbial Agents 2003; 21:354-6.
20. Ordway D, Vivueiros M, Leandro C, Bettencourt R, Almeida J, Lewis J, et al. Clinical concentration of thioridazine kill intracellular multidrug resistant Mycobacterium tuberculosis. Antimicrobial Agents Chemother 2003; 47:917- 22.
21. Katiar D, Tiwary VK, Tripathy RP, Srivastava A, Chaturvedi V, Srivastava R, et al. Synthesis and antimicrobial activity of 3, 5- disubsituted thiadiazine thiones. Bioorg Med Chem 2003; 11:4369-75.
22. Ninasanont N, Black DS, Chenphen R, Thebtaranonth Y. Synthesis of ethyl- 5-phenyl-6-oxa-1 azabicyclo [3.1.0] hexane-2-carboxylate derivative and evaluation of their antimalarial activity. J Med Chem 2003; 46:2397-403.
23. Coban AY, Bayramoglu G, Ekinci B, Durupinar B. Antibacterial effect of NO. Mikrobiyol Bul 2003;37:151-155.
24. Jimenez-Arellanes A, Meckes M, Ramirez R, Torres J, Luna-Herrera J. Activity against multidrug resistant Mycobacterium tuberculosis in Mexican plants used to treat respiratory disease. Phytother Res 2003; 17:903-8.
25. Xie JP, Yue J, Xiong YL, Wang WY, Yus Q, Wang HH. In vitro activities of small peptides from snake venom against clinical isolate of drug-resistant Mycobacterium tuberculosis. Int J Antimicrobial Agents 2003; 22:172-4.
26. Munro Aw, Mclean KJ, Marshall KR, Warman AJ, Lewis J, Roitel O, et al. Cytochrome p 450: Novel drug targets in the tuberculosis. Biochem Soc Trans 2003;31:625-30.
27. Toyohara M, Nagata A, Hayano K, Abe J. Study on the antitubercular activity of tuberactinomycin, a new antimicrobial drug. Am Rev Repir Dis 1986;100:228-30.
28. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones,
29. Furin J, Cox H, Pai M. Tuberculosis. The Lancet. 2019;393(10181):1642–1656.
30. Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nature Reviews Disease Primers. 2016 2016/10/27;2(1):16076.
31. Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis (Edinb). 2011 Nov;91(6):497–509. [PubMed: 21733755]
32. Orme IM, Basaraba RJ. The formation of the granuloma in tuberculosis infection. Seminars in Immunology. 2014;26(6):601–609. [PubMed: 25453231]
33. Yegian D Biology of tubercle bacilli in necrotic lesions. Am Rev Tuberc. 1952 Nov;66(5):629–31. [PubMed: 12986203]
34. Sarathy JP, Dartois V. Caseum: a Niche for Mycobacterium tuberculosis Drug-Tolerant Persisters. Clin Microbiol Rev. 2020 Jun 17;33(3).
35. Xie YL, de Jager VR, Chen RY, et al. Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis. Science Translational Medicine.  2021;13(579):eabd7618. [PubMed: 33536283] ** Evaluate drug combination response early in treatment with imaging in humans.
36. Strydom N, Gupta SV, Fox WS, et al. Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization. PLoS Med. 2019 Apr;16(4):e1002773. [PubMed: 30939136] ** Integrative modeling using tissue drug distributin to select optimal drug combination and dosing
37. Ernest JP, Sarathy J, Wang N, et al. Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis. Antimicrob Agents Chemother. 2021 Jul 12:AAC0050621.
38. Sarathy J, Blanc L, Alvarez-Cabrera N, et al. Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. Antimicrob Agents Chemother. 2019 May;63(5).* Measurement of drug tissue pharmacokinetics and pharmacodynamics
39. Prideaux B, Via LE, Zimmerman MD, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nature Medicine. 2015;21(10):1223–1227.
40. Sarathy JP, Zuccotto F, Hsinpin H, et al. Prediction of Drug Penetration in Tuberculosis Lesions. ACS Infectious Diseases. 2016;2(8):552–563. [PubMed: 27626295]
41. Wayne LG, Sohaskey CD. Nonreplicating persistence of mycobacterium tuberculosis. Annu Rev Microbiol. 2001;55:139–63. [PubMed: 11544352]
42. Lenaerts A, Barry CE 3rd, Dartois V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev. 2015 Mar;264(1):288–307. [PubMed: 25703567]
43. Hoff DR, Ryan GJ, Driver ER, et al. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS One. 2011 Mar 21;6(3):e17550. [PubMed: 21445321]
44. Lenaerts AJ, Hoff D, Aly S, et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother. 2007 Sep;51(9):3338–45. [PubMed: 17517834]
45. Schrader SM, Vaubourgeix J, Nathan C. Biology of antimicrobial resistance and approaches to combat it. Sci Transl Med. 2020 Jun 24;12(549).
46. Eoh H, Liu R, Lim J, et al. Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance in Mycobacterium tuberculosis. Front Cell Infect Microbiol. 2022; 12:958240. [PubMed: 36072228]
47. Iacobino A, Piccaro G, Giannoni F, et al. Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli. Int J Mycobacteriol. 2017 Jul-Sep;6(3):213–221. [PubMed: 28776518]
48. Zhang M, Sala C, Dhar N, et al. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014 Jun;58(6):3217–23. [PubMed: 24663022]
49. Raghunandanan S, Jose L, Kumar RA. Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne’s model of dormancy. J Antibiot (Tokyo). 2018 Nov;71(11):939–949. [PubMed: 30185901]
50. Betts JC, Lukey PT, Robb LC, et al. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol. 2002 Feb;43(3):717–31. [PubMed: 11929527]
51. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. 1996 Jun;64(6):2062–9. [PubMed: 8675308]
52. Karakousis PC, Williams EP, Bishai WR. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Chemother. 2008 Feb;61(2):323–31. [PubMed: 18156607]
53. Iacobino A, Piccaro G, Giannoni F, et al. Activity of drugs against dormant Mycobacterium tuberculosis. Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S94–S95. [PubMed: 28043638]
54. Fattorini L, Piccaro G, Mustazzolu A, et al. Targeting dormant bacilli to fight tuberculosis. Mediterr J Hematol Infect Dis. 2013 Nov 19;5(1):e2013072. [PubMed: 24363887]
55. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005 Jan 14;307(5707):223–7. [PubMed: 15591164]
56. Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008 Nov 28;322(5906):1392–5. [PubMed: 19039139]
57. Diacon AH, Pym A, Grobusch M, et al. The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis. New England Journal of Medicine. 2009;360(23):2397–2405. [PubMed: 19494215]
58. Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis. New England Journal of Medicine. 2022;387(9):810–823. [PubMed: 36053506]
59. Bryk R, Gold B, Venugopal A, et al. Selective killing of nonreplicating mycobacteria. Cell Host Microbe. 2008 Mar 13;3(3):137–45. [PubMed: 18329613]
60. Darby CM, Nathan CF. Killing of non-replicating Mycobacterium tuberculosis by 8-hydroxyquinoline. Journal of Antimicrobial Chemotherapy. 2010;65(7):1424–1427. [PubMed: 20435781]
61. Grant SS, Kawate T, Nag PP, et al. Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model. ACS Chem Biol. 2013 Oct 18;8(10):2224–34. [PubMed: 23898841]
62. Gold B, Smith R, Nguyen Q, et al. Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis. Journal of Medicinal Chemistry. 2016;59(13):6027–6044. [PubMed: 27144688]
63. Chatterjee D, Bonnett SA, Dennison D, et al. A class of hydrazones are active against non-replicating Mycobacterium tuberculosis. Plos One. 2018;13(10).
64. Neyrolles O, Flint L, Korkegian A, et al. InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis. Plos One. 2020;15(11).
65. Balaban NQ, Helaine S, Lewis K, et al. Definitions and guidelines for research on antibiotic persistence. Nature Reviews Microbiology. 2019;17(7):441–448. [PubMed: 30980069]
66. Aldridge BB, Fernandez-Suarez M, Heller D, et al. Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility. Science. 2012 Jan 6;335(6064):100–4. [PubMed: 22174129]
67. Schrader SM, Botella H, Jansen R, et al. Multiform antimicrobial resistance from a metabolic mutation. Sci Adv. 2021 Aug;7(35).
68. Levin-Reisman I, Ronin I, Gefen O, et al. Antibiotic tolerance facilitates the evolution of resistance. Science. 2017 Feb 24;355(6327):826–830. [PubMed: 28183996]
69. Liu J, Gefen O, Ronin I, et al. Effect of tolerance on the evolution of antibiotic resistance under drug combinations. Science. 2020 Jan 10;367(6474):200–204. [PubMed: 31919223]
70. Schrader SM, Botella H, Jansen R, et al. Multiform antimicrobial resistance from a metabolic mutation. Science Advances. 2021;7(35).
71. Iacobino A, Piccaro G, Giannoni F, et al. Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli [Review Article]. International Journal of Mycobacteriology. 2017 July 1, 2017;6(3):213–221. [PubMed: 28776518]
72. McGrath M, Gey van Pittius NC, van Helden PD, et al. Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2014 Feb;69(2):292–302. [PubMed: 24072169]
73. Ford CB, Shah RR, Maeda MK, et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet. 2013 Jul;45(7):784–90. [PubMed: 23749189]
74. Coelho T, Machado D, Couto I, et al. Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil. Frontiers in Microbiology. 2015;6.
75. Laws M, Jin P, Rahman KM. Efflux pumps in Mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance. Trends in Microbiology. 2022;30(1):57–68. [PubMed: 34052094]
76. Pyle MM. Relative numbers of resistant tubercle bacilli in sputa of patients before and during treatment with streptomycin. Proc Staff Meet Mayo Clin. 1947 Oct 15;22(21):465–73. [PubMed: 20267460]
77. Palaci M, Dietze R, Hadad DJ, et al. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol. 2007 Dec;45(12):4064–6. [PubMed: 17928422]
78. British Medical Journal. Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council Investigation. Bmj. 1948;2(4582):769–782. [PubMed: 18890300]
79. British Medical Journal. Streptomycin in Pulmonary Tuberculosis. Bmj. 1948;2(4582):790–791. [PubMed: 20787428]
80. Bahuguna A, Rawat DS. An overview of new antitubercular drugs, drug candidates, and their targets. Med Res Rev. 2020 Jan;40(1):263–292. [PubMed: 31254295]
81. Campanico A, Moreira R, Lopes F. Drug discovery in tuberculosis. New drug targets and antimycobacterial agents. Eur J Med Chem. 2018 Apr 25; 150:525–545. [PubMed: 29549838] a new class of synthetic antimicrobials. Pharmacotherapy 1998; 18:456-62.
82. Grosset J The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc. 1978 Mar;53(1):5–12. [PubMed: 656653]
83. Xu J, Li SY, Almeida DV, et al. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. Antimicrob Agents Chemother. 2019 May;63(5).
84. Lanoix JP, Betoudji F, Nuermberger E. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis. Antimicrob Agents Chemother. 2016 Feb;60(2):1091–6. [PubMed: 26643352]
85. Lanoix JP, Lenaerts AJ, Nuermberger EL. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech. 2015 Jun;8(6):603–10. [PubMed: 26035868]
86. Lee BY, Clemens DL, Silva A, et al. Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility. PLoS One. 2018;13(11):e0207469. [PubMed: 30427938]
87. Saini V, Ammerman NC, Chang YS, et al. Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis. Antimicrob Agents Chemother. 2019 Jun;63(6).